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CYSTATIN C IS A MORE SENSITIVE ESTIMATE OF KIDNEY FUNCTION
THAN CREATININE IN PEDIATRIC AUTOLOGOUS BONE MARROW
TRANSPLANTATION
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Overview: Accurate assessment of kidney function is essential in the
care of bone marrow transplant (BMT) patients. Both cystatin C,
a protease inhibitor produced by all nucleated cells and measured
in a single blood sample, and creatinine are used to estimate kidney
function (glomerular filtration rate, GFR).While creatinine is influ-
enced by muscle mass, cystatin C is potentially modified by cortico-
steroids, thyroid function, and the white blood cell count (WBC).
The literature is conflicting on the validity of cystatin C measure-
ments in BMT and oncology patients, and the effect of leukopenia
is understudied. We hypothesize that cystatin C is a more sensitive
estimate of kidney function in BMT patients, while controlling for
the WBC.
Methods:We retrospectively compared cystatin C to creatinine for
predicting nuclear GFR (technetium-99m-DTPA; nucGFR) in pe-
diatric recipients of autologous BMTs. General linear mixed models
were used to calculate regression and intra-class correlation coeffi-
cients (ICC, ranging from 0-1 with higher values indicating less var-
iation/greater reliability between the estimates). Prediction models
used cystatin C GFR5 [77.24*cys21.2623] (cysGFR), with and with-
out WBC, and Schwartz GFR 5 [0.413*height (cm)/creatinine]
(schGFR).
Results: 12 patients (median age 3.5 yrs, range 2-10 yrs) underwent
29 tandem BMTs (median 2 BMTs/patient, range 1-4) for medullo-
blastoma (n5 7), neuroblastoma (n5 4), and atypical teratoid rhab-
doid tumor (n 5 1). All patients except 1 had normal thyroid
function. 3 patients received steroids (2 stress dosing and 1 high-
dose for veno-occlusive disease of the liver). GFRs (mean6std error)
in ml/min/1.73m2 (normal . 90) were 142.069.0 (nuc), 136.566.2
(cys), and 132.165.1 (sch). ICCs were 0.54 for nucGFR versus
cysGFR and 0.26 for nucGFR versus schGFR. Furthermore, the
Pearson correlation coefficient was much higher for cysGFR (0.80,
p\0.001) than for schGFR (0.22, p5 0.36) compared to nucGFR.
Regression coefficients and the 95% confidence intervals (CI) for the
prediction models are shown in the table.
Conclusions: Cystatin C was a statistically significant predictor of
nucGFR while creatinine was not. WBC was of borderline signifi-
cance in prediction of nucGFR using cysGFR. To maximize clinical
utility, future research will confirm these findings by accounting for
additional confounders in a larger group of patients and a wider
range of GFR.
Independent
predictors in
model for nucGFR b regression coefficients [95% CI]cysGFR* 0.96 [0.77, 1.14]
cysGFR* & WBC 1.08 [0.94, 1.23] & 0.67 [-1.02, 2.36]
schGFR 0.17 [-0.072, 0.41]*statistically significant (p<0.05)294
A MULTIDISCIPLINARY APPROACH TO ADHERENCE IMPROVEMENT US-
ING EDUCATION AND MEDICATION BOXES FOR ADOLESCENTS AND
YOUNG ADULTS WHO HAVE UNDERGONE ALLOGENEIC HEMATO-
POEITIC STEM CELL TRANSPLANTATION
McBride, J., Shinkle, M. Children’s Memorial Hospital, Chicago, IL
Achieving adherence to immunosuppressive medications in the
adolescent population of post allogeneic stem cell transplant canbe challenging. Literature has documented consistently a link be-
tween regimen complexity and adherence rates. Non-adherence
can put patients at increase risk of uncontrolled graft versus host dis-
ease. While there is literature describing adolescent barriers to ad-
herence and their attitudes regarding medications, no studies have
evaluated the use of medication boxes in combination with a multi-
disciplinary patient education on adherence. A pilot study was un-
dertaken to see if use of a medication box combined with a 15
minute discussion with a pharmacist and social worker about barriers
to adherence, the importance of medication adherence, and how to
use the box will improve adherence in adolescent post allogeneic
stem cell transplant patients. Medication boxes were initially filled
by a health care professional on the patients’ clinic day. Pill counts
were used to assess adherence rates. Patients completed surveys
about their perception on their medications prior to, during, and af-
ter the intervention. 11 patients consented to study to date (ages 13-
25); 1 patient withdrew, 1 patient died prior to start of the study, and
1 patient has yet to start. During the active medication box phase of
the study, patient’s adherence rates ranged from 57-100% with all
but one patient having an adherence rate . 80%. When study par-
ticipants where asked if they do a good job caring for themselves 7
out of 9 responded positively (somewhat to strong agreement); al-
though, 5 out of 8 reported missed doses at least once during the
study duration. Of note, 6 out of 9 participants at some point during
the study duration reported agreement or neutrality to the statement
‘I don’t think I need my medication’ and 8 out of 9 patients reported
agreement or neutrality to the statement ‘My doctors want me to
take too many medications’. These findings are of interest because
they may reflect unique characteristics of adolescent development,
how their views on their health and medications may change
throughout a treatment course, whichmay have direct effect onmed-
ication adherence. This pilot study supports the use of medication
boxes for adolescents post allogeneic stem cell transplantation. Fur-
ther studies need to be done to assess what patients would most ben-
efit by having their medication box filled for them.295
ENGRAFTMENT KINETICS IN CHILDREN AFTER REDUCED INTENSITY
CONDITIONING HEMATOPOIETIC STEM CELL TRANSPLANTATION (RIC-
HSCT)
Schneiderman, J., Kletzel, M., Chaudhury, S., Duerst, R., Tse, W.T.
Northwestern University Feinberg School of Medicine, Children’s Memo-
rial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
The kinetics of stem cell engraftment following RIC-HSCT are
different from that of myeloablative transplant; previous analyses
are limited to adults. Between 2003 and 2010, we performed RIC-
HSCT in 88 children with malignant (n 5 40) or non-malignant
(48) diseases; none had prior HSCT. Patient characteristics are
shown in Table 1. Post-HSCT, total white cells donor chimerism
was monitored serially by variable number tandem repeat analysis
once the peripheral white blood cell count exceeded 1,000 cells/
ml. The cumulative incidence of patients reaching 50% and 90%do-
nor chimerism by +20/40/60 days post-HSCT was 67/85/86% and
41/68/72%, respectively. Eight patients (8/88 5 9%) had primary
graft failure, with chimerism never reaching 20%. Sixty-six patients
(75%) have peak chimerism over 90%, whereas 14 patients (16%)
have peak chimerism between 20-90%. Among those engrafted (n
5 82), chimerism in 57 patients (70%) was durable and did not de-
cline with time, but in 25 patients (30%), there was a drop in chime-
rism of . 10% between two consecutive measurements. Median
time of chimerism drop was +60 days post-HSCT (range 17-193
days). Seven patients (7/82 5 8%) experienced relapse of leukemia
soon after the drop was detected, 12 patients (15%) had stabilization
or improvement of chimerism after withdrawal of immunosuppres-
sion and/or donor lymphocyte infusion (DLI), and 6 patients (7%)
had no recovery despite immune manipulation, resulting in second-
ary graft failure. There is no correlation between the magnitude of
chimerism drop and the response to immune manipulation. There
were differences in engraftment kinetics among patients with malig-
nant or non-malignant diseases. In the malignant group, the cumu-
lative incidence of 90% donor chimerism at +100 days was 87.5%,
and at one year, the percentage of patients with full or mixed chime-
rism was 90% and 10%, respectively. By contrast, in the non-
